We are boosting cell rejuvenation to treat currently incurable neurodegenerative and rare genetic diseases
Autophagy (from the Ancient Greek: ”self-eating”) is the cell’s main method for recycling damaged components and this process declines with age. There is compelling evidence that boosting autophagy leads to increased healthspan and lifespan, while impaired autophagy drives many serious diseases.
We are enhancing healthspan, by building an unbiased data-driven drug discovery engine
We’re letting our proprietary data guide us in new and unexpected directions to find better ways to restore autophagy. This approach allows us to uncover novel biology and gives us fundamental insights into how the cell controls this process. It’s led us very quickly to first in class, disease modifying programs which have exciting therapeutic activity.
Samsara Therapeutics Establishes Scientific Advisory Board
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics
More additions to the Samsara Therapeutics team
We’re pleased to report that we’ve further strengthened our team in Oxford.
Neurodegeneration, lysosomal dysfunction and autophagy
There is a desperate need for novel therapies that can prevent the progressive neurodegeneration in debilitating diseases of ageing, such as Alzheimer’s, Parkinson’s and Huntington’s Disease.
New home and strengthening our scientific team
It’s a busy time for Samsara Therapeutics as we move into our new purpose-built labs and offices in the Wood Centre for Innovation in Oxford.
© 2021 Samsara Therapeutics | Legal Information | Privacy
© 2021 Samsara Therapeutics
Legal Information | Privacy